14 November 2024 - After re-examining its initial opinion, EMA’s CHMP has recommended granting a marketing authorisation to Leqembi (lecanemab) for treating mild cognitive impairment or mild dementia due to Alzheimer’s disease (early Alzheimer’s disease) in patients who have only one or no copy of ApoE4, a certain form of the gene for the protein apolipoprotein E.

Patients with only one or no copy of ApoE4 are less likely to experience amyloid-related imaging abnormalities than people with two ApoE4 copies.

Read EMA press release